Teva launched generic Protonix on December 21, 2007. Wyeth’s own generic version of Protonix, a gastrointestinal drug, will be distributed by Prasco.
Bernard Poussot, president and CEO of Wyeth, said: “We believe the Protonix compound patent is strong and we will vigorously pursue our litigation against Teva and other infringing generics. Going forward, we will continue to seek an injunction against any infringement of this patent, as well as monetary damage, including lost profits, from Teva.”